心脏手术中应用结合珠蛋白与术后急性肾损伤风险的关联
该单中心回顾性观察研究纳入2008至2015年需体外循环的心脏手术患者1326例,排除术前需肾脏替代治疗及降主动脉置换者。校正OR 0.54 [0.31,0.93])。
要点
- 倾向性评分匹配后,术中应用结合珠蛋白与术后AKI风险降低独立相关。
- 该研究为单中心回顾性观察,结论属假设生成性质,需前瞻性研究验证。
- 研究排除了术前需肾脏替代治疗及降主动脉置换的患者。
核心结论
- 在心血管手术患者中,术中应用结合珠蛋白与术后急性肾损伤风险降低独立相关。
研究设计与样本
- 单中心回顾性观察研究,筛选2008至2015年需体外循环的心脏手术患者,排除术前需肾脏替代治疗及降主动脉置换者,最终纳入1326例。
- 采用倾向性评分匹配模型调整混杂因素,匹配后每组249例(共498例),并进一步建立逻辑回归模型进行敏感性分析。
主要发现
- 总队列AKI发生率为25.5%(338例),260例(19.6%)患者术中应用了结合珠蛋白。
临床怎么用
- 对于体外循环心脏手术患者,术中应用结合珠蛋白可能有助于降低术后急性肾损伤风险,但需结合患者具体情况并等待前瞻性研究证实。
局限性
- 本研究为单中心回顾性观察性研究,结论属假设生成性质,可能存在残余混杂。
- 研究排除了术前需肾脏替代治疗及降主动脉置换的患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute kidney injury (AKI) often occurs after cardiac surgery. During cardiac surgery, plasma free hemoglobin (fHb) would increase due to hemolysis. Since plasma fHb is thought to be nephrotoxic, haptoglobin, which is an fHb scavenger, may have the potential to prevent postoperative AKI (pAKI). However, there have been few studies in which the association of intraoperative administration of haptoglobin with the incidence of AKI after cardiac surgery was assessed. METHODS: This study was a retrospective observational study to assess the independent association of intraoperative administration of haptoglobin with the incidence pAKI in cardiac surgery patients. We screened cardiac surgery patients who required cardiopulmonary bypass from 2008 to 2015. We excluded patients who required renal replacement therapy preoperatively. We also excluded patients in whom descending aortic replacement was performed. pAKI was defined according to AKI Network criteria. A propensity score-matched model was used to adjust confounders. For sensitive analysis, we further developed a logistic regression model. RESULTS: We included 1326 patients in this study. The incidence of AKI in the total cohort was 25.5% (338 patients). Haptoglobin was administered in 260 patients (19.6%). In the crude cohort, the incidence of AKI in patients with haptoglobin administration was 24.6%, which was not significantly different from the incidence of 25.7% in those without haptoglobin administration (P = .72; odds ratio, 0.94 [95% confidence interval, 0.69-1.29]). After propensity score matching, we had 249 patients in each group (for a total of 498 patients). In this propensity score-matched cohort, the incidence of AKI in patients with haptoglobin administration was 22.5%, which was significantly lower than the incidence of 30.9% in those without haptoglobin administration (P = .033; odds ratio, 0.65 [0.43-0.97]). In our logistic regression model for the risk of pAKI, haptoglobin administration was independently associated with decreased risk of AKI (P = .029; adjusted odds ratio, 0.54 [0.31, 0.93]). CONCLUSIONS: In this hypothesis-generating, single-center retrospective observational study, intraoperative administration of haptoglobin was independently associated with lower risk of AKI after cardiovascular surgery.
引用
- Kubota K, Egi M, Mizobuchi S, et al. Haptoglobin Administration in Cardiovascular Surgery Patients: Its Association With the Risk of Postoperative Acute Kidney Injury. Anesth Analg. 2017. PMID: 28525506. doi:10.1213/ANE.0000000000002093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。